Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.

Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS, Swanton C, Quezada SA.

Ann Oncol. 2018 Jan 1;29(1):271-279. doi: 10.1093/annonc/mdx687.

2.
3.

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD.

Nature. 2017 Nov 23;551(7681):517-520. doi: 10.1038/nature24473. Epub 2017 Nov 8.

4.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

5.

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA.

Science. 2018 Feb 2;359(6375):582-587. doi: 10.1126/science.aao4572. Epub 2017 Dec 7.

6.

[Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].

Dissemond J, Grabbe S.

Hautarzt. 2006 Aug;57(8):690-6. Review. German.

PMID:
16163561
7.

Tools to define the melanoma-associated immunopeptidome.

Bräunlein E, Krackhardt AM.

Immunology. 2017 Dec;152(4):536-544. doi: 10.1111/imm.12803. Epub 2017 Aug 28. Review.

8.

Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.

Ohnmacht GA, Marincola FM.

J Cell Physiol. 2000 Mar;182(3):332-8. Review.

PMID:
10653599
9.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T, Kvist A, Ringnér M, Svane IM, Jönsson G.

Nat Commun. 2017 Nov 23;8(1):1738. doi: 10.1038/s41467-017-01460-0.

10.

Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.

Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E.

Cancer Res. 2005 May 1;65(9):3937-41.

11.

Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.

Kim S, Kim HS, Kim E, Lee MG, Shin EC, Paik S, Kim S.

Ann Oncol. 2018 Apr 1;29(4):1030-1036. doi: 10.1093/annonc/mdy022.

PMID:
29360924
12.

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10.

13.

Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.

Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N.

J Immunol. 2015 Jul 1;195(1):356-66. doi: 10.4049/jimmunol.1403145. Epub 2015 May 22.

14.

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.

Clin Cancer Res. 2009 Aug 1;15(15):4968-77. doi: 10.1158/1078-0432.CCR-08-3320. Epub 2009 Jul 14.

15.

Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma.

Kubecek O, Trojanova P, Molnarova V, Kopecky J.

Med Hypotheses. 2016 Aug;93:74-6. doi: 10.1016/j.mehy.2016.05.023. Epub 2016 May 21.

PMID:
27372860
16.

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.

Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H.

Cancer Immunol Immunother. 2005 Mar;54(3):208-18. Epub 2004 Sep 21.

PMID:
15449035
17.

The Immunology of Melanoma.

Ko JS.

Clin Lab Med. 2017 Sep;37(3):449-471. doi: 10.1016/j.cll.2017.06.001. Review.

PMID:
28802495
18.

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. Epub 2016 Nov 11.

19.

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, Sansregret L, Gore M, Larkin J, Quezada SA, Swanton C.

Lancet Oncol. 2017 Aug;18(8):1009-1021. doi: 10.1016/S1470-2045(17)30516-8. Epub 2017 Jul 7.

20.

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.

Hellmann MD, Snyder A.

Immunity. 2017 Aug 15;47(2):221-223. doi: 10.1016/j.immuni.2017.08.001.

Supplemental Content

Support Center